Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 3/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13647857 | 0.88 | CDK2 (0.37) | EGFRGAACDK2CCNE2CCNE1 | |
| SCHEMBL13647855 | 0.88 | TNK2 (0.36) | CDK2TAAR1JAK3MAPK10FGFR1 | |
| SCHEMBL2854241 | 0.87 | SYK (0.37) | CDK2CCNE1TAAR1JAK3MAPK10 | |
| SCHEMBL2860934 | 0.87 | GSK3B (0.38) | EGFRMAPK10AURKARPS6KB1IKBKB | |
| SCHEMBL13513925 | 0.86 | TSHR (0.37) | GAACDK2JAK3HCRTR1HCRTR2 | |
| SCHEMBL13647864 | 0.86 | CDK2 (0.36) | EGFRGAACDK2CCNE2CCNE1 | |
| SCHEMBL13647859 | 0.86 | CDC7 (0.39) | CDK2TAAR1JAK3MAPK10HCRTR1 | |
| SCHEMBL14489538 | 0.85 | TAAR1 (0.44) | POLBCDK2TAAR1JAK3MAPK10 | |
| SCHEMBL13513952 | 0.85 | SYK (0.36) | CDK2CCNE1TAAR1JAK3MAPK10 | |
| SCHEMBL13647862 | 0.81 | LMNA (0.39) | POLBEGFRCDK2RECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598245-B2 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598245-B2 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-04-24 | — | — | US | disclosed |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-04-24 | — | — | US | disclosed |
| US-7226920-B2 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226920-B2 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | MAP3K20, MAP3K5, MAP3K1 | POLB 1763/4885EGFR 942/4885ERBB2 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.